Hypoxia-inducible factor 1 (HIF-1) mediates transcriptional responses to hypoxia. HIF-1 is composed of an O2-and growth factor-regulated HIF-loc subunit and a constitutively-expressed HIF-1 (3 subunit. Four lines of evidence indicate that HIF-1 contributes to tumor progression. First, HIF-1 controls the expression of gene products that stimulate angiogenesis, such as vascular endothelial growth factor, and promote metabolic adaptation to hypoxia, such as glucose transporters and glycolytic enzymes, thus providing a molecular basis for involvement of HIF-1 in tumor growth and angiogenesis. Second, in mouse xenograft models, tumor growth and angiogenesis are inhibited by loss of HIF-1 activity and stimulated by HIF-la overexpression. Third, immunohistochemical analyses of humantumor biopsies indicate that HIF-la is overexpressed in common cancers and that the level of expression is correlated with tumor grade, angiogenesis, and mortality. Fourth, in addition to intratumoral hypoxia, genetic alterations in tumor suppressor genes and oncogenes induce HIF-1 activity. (Internal Medicine 41 : 79-83, 2002) 
Introduction
The initial discoveries of molecular oncology focused on genes that when mutated resulted in increased cellular proliferation because this was a phenotype that could be easily assayed in tissue culture. The discovery of the crucial role of angiogenesis in tumor progression ( 1 ) has provided an example of a critical aspect of cancer biology that could not be well studied ex vivo. It has also focused attention on the metabolic requirements of tumor cells, as angiogenesis occurs as a response to tissue hypoxia (reviewed in ref. 2 ). In addition, many commonly-occurringmutations in oncogenes and tumor suppressor genes that result in increased cell proliferation have been found to also stimulate angiogenesis (2) . Intratumoral microvascular density has been shown to be of prognostic significance in many commonhumancancers (3) (4) (5) . Remarkably whencervical cancers and soft tissue sarcomasthat are accessible to Eppendorfmicroelectrode measurementsof intratumoral PO2have been studied, a significant association has been observed between intratumoral hypoxia (PO2 <10 mm Hg or 1.5% O2) and invasion, metastasis, treatment failure, and patient death (6, 7) . Thus, tumor progression is associated both with angiogenesis and intratumoral hypoxia. The basis for this apparent paradox is that tumor vasculature is structurally and functionally abnormal resulting in perfusion that is spatially and temporally heterogeneous (8) . An important conclusion drawn from these findings is that tumor cell survival is dependent upon adaptation to O2 concentrations far below those present in normal tissue (reviewed in ref.
2).
Regulation of Gene Expression by HIF-1
Whencells are exposed to hypoxia or growth factors, HIFloc accumulates within the nucleus, dimerizes with HIF-1 (3, binds to target genes in a sequence-specific manner, and activates their transcription. Over 40 different HIF-1 target genes have been identified and the majority of these are known to play important roles in tumor progression such as angiogenesis, cell proliferation or survival, remodeling of the extracellular milieu, glucose metabolism, and iron homeostasis (Table  1 ; see ref. 9 for citations). Proteins encoded by these genes, such as vascular endothelial growth factor (VEGF) mediate increased O2 delivery via new blood vessel formation. Other protein products of HIF-1-regulated genes, such as glucose transporters and glycolytic enzymesallow the cell to adapt their metabolism to an O2-deprived environment. Finally, expression of a third group of gene products may influence the balance betweenapoptotic and anti-apoptotic signals that detemines cell survival. In addition to the role of HIF-1 as a DNAbinding protein, HIF-1a has also been shownto exert biological effects via protein-protein interactions. Under hypoxic conditions HIF-1 a has been shown to interact with the tumor suppressor protein p53, which is itself a DNA-binding transcription factor. This interaction appears to increase the half-life of p53 (10) by MDM2, a ubiquitin protein ligase that binds to p53 (ll). The HIF-la-mediated stabilization of p53 may contribute to hypoxia-mediated apoptosis, which mayin turn represent a critical selective force for p53 loss of function (12) .
Effect of Altering HIF-1 Activity in Mouse Xenograft Models
In order to determine whether HIF-1 activity is important for tumorigenesis, cultured tumor cell lines which have been genetically altered to increase or decrease HIF-1 activity have been analyzed in mouse xenograft assays. Loss of HIF-1 activity is associated with decreased angiogenesis and tumor growth (13) (14) (15) (16) (17) (18) . Forced overexpression of HIF-la in HCT116 human colon carcinoma cells results in increased growth, vascular density, and vascular permeability of tumor xenografts ( 1 1 ). In addition to stimulation of angiogenesis, tumor xenograft growth is also stimulated by HIF-1 via its activation of glycolytic metabolism as a meansof maintaining ATPlevels under conditions of reduced O2 availability (19) . These data indicate that the increased HIF-l a expression observed in human tumor biopsies (see below) is not an epiphenomenon but is an important factor contributing to tumor progression and clinical outcome.
Expression of HIF-la in HumanCancer and its Clinical Significance
In order to analyze the expression of HIF-la in human tumor biopsies, monoclonal antibodies were generated and immunohistochemical assays were developed (20, 21) . Analysis of an increasing numberof common humancancers has resuited in several important findings (Table 2) . HIF-loc is overexpressed in most common humancancers, including breast, brain, cervical, colon, lung, ovarian, and prostate cancer. Significant tumor-specific associations have been found between HIF-l oc overexpression and a variety of biomarkers including Ki67 (proliferation), VEGF or MVD(angiogenesis), and mutant p53 (resistance against apoptosis) (21) (22) (23) (24) (25) . The most interesting and important results, however, have addressed the relationship of HIF-loc overexpression to overall survival, as described below. In early-stage cervical carcinoma, HIF-loc overexpression is correlated with patient mortality (26) . In early-stage esophageal cancer, HIF-l oc overexpression is correlated with failure to achieve a complete response to photodynamictherapy (27) . In oropharyngeal squamouscell carcinoma, the degree of HIFl oc overexpression is correlated with both radiation resistance and patient mortality (28) . In contrast, HIF-l oc overexpression is correlated with patient survival and increased apoptosis in non-small cell lung carcinoma (29) . A recent analysis of ovarian cancers (22) provides important data that help interpret the lung cancer data. In ovarian cancer, HIF-l oc overexpression was correlated with apoptotic rate as in the lung cancer study. However, in ovarian cancers expressing mutant p53, HIF-loc overexpression was not associated with apoptosis. Furthermore, the combination of mutant p53 and HIF-l oc overexpression was associated with a highly significant (p<0.0001) seven-fold increased relative risk of patient mortality (22) . In the study of early-stage esophageal cancer discussed above, the combination of HIF-loc overexpression and expression of the antiapoptotic protein Bcl2 was significantly associated with treatment failure (27) . Animportant but not surprising conclusion is that the con- sequences of HIF-la overexpression in a tumor are dependent upon the cancer type, tumor grade/stage, and/or the presence of other genetic alterations, especially mutations that inactivate pro-apoptotic tumorsuppressors or activate anti-apoptotic oncoproteins. Most importantly, the finding of particular subpopulations of cancer patients in which HIF-l a overexpression results in a greatly increased risk of mortality mayprovide a means of identifying, at the time of initial diagnosis, patients whorequire more aggressive therapy in order to survive their disease.
Molecular Basis of HIF-la Overexpression in
HumanCancer
As described above, intratumoral hypoxia represents a major selective force during tumor progression. The adaptation to hypoxia occurs via two mechanisms. First, hypoxia directly increases the half-life of HIF-la by decreasing the rate of ubiquitination and proteasomal degradation of the protein (30) (31) (32) (33) . Recent studies have demonstrated that the tumor suppressor protein VHLinteracts with HIF-la and targets the protein for ubiquitination (34) (35) (36) and that VHLloss of function results in the constitutive high-level expression of HIF-la (37) . The binding of VHLrequires hydroxylation of HIF-l a on proline 564 by an enzyme that requires O2, iron, and oxoglutarate as substrates, which is characteristic of prolyl-4-hydroxylases (38, 39) .
In addition to the effects of intratumoral hypoxia on the halflife of HIF-la, growth factor stimulation also induces HIF-la expression (40) . In the case of signaling via the HER2neure-ceptor, activation of a signal transduction pathway involving phosphatidylinositol-3-kinase (PI3K) and the serine-threonine kinases AKT (protein kinase B) and FKBP-rapamycin-associated protein (mammalian target of rapamycin) has been shown to result in a dramatic increase in HIF-la protein synthesis (41) . Thus, gain-of-function mutations in oncogenes which activate growth factor-PI3K signaling pathways lead to increased HIF-la expression via this mechanism, as do loss-of-function mutations in the tumor suppressor gene encoding PTEN,a phosphatase that negatively regulates the PI3K pathway (42, 43) . Activation of SRC, which lies downstream of receptor tyrosine kinases and upstream of the PI3K pathway, also induces HIFla expression ( 14) . Most recently, the tumor suppressor pl4ARF has been shownto sequester HIF-loc in the nucleolus such that p l 4ARFloss-of-function increases HIF-1 DNA-binding and transcriptional activity in cancer cells (44) . Thus, the high level expression of HIF-1a in humancancers demonstrated by immunohistochemistry results both as a response to the physiological stimulus of hypoxia and as a result of tumor-specific genetic alterations (Table 3 ). The induction of HIF-1 activity provides a basis for the observation that mutations in oncogenes and tumor suppressor genes result in stimulation of VEGFexpression and angiogenesis as well as the induction of aerobic glycolysis, also known as the Warburg effect (2).
Translating Basic Research into Clinical
Applications Dothe basic science discoveries summarizedabovehave potential clinical applications? First, HIF-1a immunohistochemistry on standard formalin-fixed and paraffin-embedded tumor biopsies obtained at the time of initial diagnosis may be useful in identifying individuals at high risk of failing standard therapy. The studies performed to date suggest that this approach maybe useful for entire cancer types (e.g. oropharyngeal squamouscell cancer) or for certain subpopulations of patients (e.g. early-stage invasive cervical cancer) or may be useful in combination with other biomarkers (e.g. Bcl2 or mutant p53). Thus, for each cancer type the relationship of HIFloc expression to disease outcomemust be established. Subsequently, clinical trials will be necessary to determine whether more intensive clinical regimens may prolong survival of patients with HIF-1 a-overexpressing cancers. Second, a small molecule inhibitor of HIF-1 activity may be of therapeutic utility. Here, the issue of a therapeutic window is of great importance since complete systemic inhibition Table 3 . Molecular Mechanisms Underlying Increased HIF-1 Activity of HIF-1activity wouldnot be tolerated. However,because tumorcells are morehypoxicand express higher levels of HIFla than normalcells, a therapeutic windowmayexist. Particularly appealing is the potential effect of combinationtherapy utilizing an angiogenesisinhibitor, whichwouldcut off the tumor's supply of oxygen,anda HIF-1inhibitor, whichwould prevent hypoxicadaptation. High-throughputscreening for inhibitors of HIF-1 -mediated gene transcription, presently being performedby the Developmental Therapeutics Programof the National Cancer Institute (45) , mayidentify small molecules for use in proof-of-principle studies in animal modelsand as lead compounds for the development of novelchemotherapeutic agents suitable for clinical testing.
